KTX-105

KTX-105 is a **preclinical targeted protein degrader** being developed by **Kymera Therapeutics** for hematologic malignancies, particularly **anaplastic large-cell lymphoma** and **peripheral T-cell lymphoma**. It is described as a **selective STAT3 degrader** that uses a heterobifunctional small-molecule protein degradation approach to recruit an **E3 ubiquitin ligase** to **signal transducer and activator of transcription 3**, driving ubiquitination and subsequent proteasomal degradation of STAT3 rather than simple occupancy-based inhibition. Preclinical reports indicate reduction of STAT3 expression, suppression of STAT3-dependent signaling, and antitumor activity in lymphoma models, including ALCL and other T-cell lymphoma systems. Publicly available information does not clearly identify the specific E3 ligase, dosage form, or route of administration for KTX-105.

Other names

selective STAT3 degrader